Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] jumped around 0.14 points on Monday, while shares priced at $8.82 at the close of the session, up 1.61%. The company report on November 13, 2023 at 8:10 AM that Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program.
Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneous injectable olanzapine for schizophrenia.
Phase 3 data expected in the second half of 2024.
Teva- Pharmaceutical Industries Ltd. ADR stock is now -3.29% down from its year-to-date (YTD) trading value. TEVA Stock saw the intraday high of $8.99 and lowest of $8.55 per share. The company’s 52-week high price is 11.44, which means current price is +24.49% above from all time high which was touched on 01/12/23.
Compared to the average trading volume of 8.24M shares, TEVA reached a trading volume of 10347361 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Teva- Pharmaceutical Industries Ltd. ADR [TEVA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TEVA shares is $10.62 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TEVA stock is a recommendation set at 2.69. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Teva- Pharmaceutical Industries Ltd. ADR shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on July 06, 2023.
The Average True Range (ATR) for Teva- Pharmaceutical Industries Ltd. ADR is set at 0.31, with the Price to Sales ratio for TEVA stock in the period of the last 12 months amounting to 0.65. The Price to Book ratio for the last quarter was 1.43, with the Price to Cash per share for the same quarter was set at 2.01. Price to Free Cash Flow for TEVA in the course of the last twelve months was 5.07 with Quick ratio for the last quarter at 0.65.
How has TEVA stock performed recently?
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.54. With this latest performance, TEVA shares gained by 1.85% in over the last four-week period, additionally plugging by 9.29% over the last 6 months – not to mention a drop of -6.17% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TEVA stock in for the last two-week period is set at 48.81, with the RSI for the last a single of trading hit 51.30, and the three-weeks RSI is set at 47.62 for Teva- Pharmaceutical Industries Ltd. ADR [TEVA]. The present Moving Average for the last 50 days of trading for this stock 9.30, while it was recorded at 8.89 for the last single week of trading, and 8.92 for the last 200 days.
Teva- Pharmaceutical Industries Ltd. ADR [TEVA]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Teva- Pharmaceutical Industries Ltd. ADR [TEVA] shares currently have an operating margin of +17.96 and a Gross Margin at +46.68. Teva- Pharmaceutical Industries Ltd. ADR’s Net Margin is presently recorded at -15.78.
Return on Total Capital for TEVA is now 8.36, given the latest momentum, and Return on Invested Capital for the company is -8.02. Return on Equity for this stock declined to -26.42, with Return on Assets sitting at -5.21. When it comes to the capital structure of this company, Teva- Pharmaceutical Industries Ltd. ADR [TEVA] has a Total Debt to Total Equity ratio set at 274.21. Additionally, TEVA Total Debt to Total Capital is recorded at 73.28, with Total Debt to Total Assets ending up at 49.21. Long-Term Debt to Equity for the company is recorded at 246.32, with the Long-Term Debt to Total Capital now at 65.83.
Reflecting on the efficiency of the workforce at the company, Teva- Pharmaceutical Industries Ltd. ADR [TEVA] managed to generate an average of -$214,683 per employee. Receivables Turnover for the company is 3.69 with a Total Asset Turnover recorded at a value of 0.33.Teva- Pharmaceutical Industries Ltd. ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.65 and a Current Ratio set at 1.00.
Earnings analysis for Teva- Pharmaceutical Industries Ltd. ADR [TEVA]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TEVA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Teva- Pharmaceutical Industries Ltd. ADR go to 1.60%.
Insider trade positions for Teva- Pharmaceutical Industries Ltd. ADR [TEVA]
The top three institutional holders of TEVA stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in TEVA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in TEVA stock with ownership which is approximately 5.7994%.